Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the PTX-100 trial which is demonstrating a good safety profile at the highest dose of 2000 mg/m2. He said: “It is very exciting to see PTX-100 show clinical activity in a patient population that is notoriously difficult to treat, and where these patients have failed several lines of prior therapies."
Prescient Therapeutics PTX-100 continues to exhibit excellent safety profile
